CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell non-Hodgkin's lymphoma (such as diffuse large B-cell lymphoma or high-grade B-cell lymphoma).
- Your lymphoma has returned after treatment or did not respond well enough to initial therapy.
- You have a high-risk factor, like lymphoma outside the lymph nodes, a tumor larger than 5 cm, or a TP53 gene change.
- You are well enough for a stem cell transplant and are scheduled to receive one followed by CAR-T therapy.
- Your heart, kidney, and liver functions are adequate, and your oxygen level is normal.
- You have not had a prior stem cell transplant or CAR-T therapy targeting CD19.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
This trial tests a personalized treatment using your own immune cells (called CAR-T cells) that are modified in a lab to target and kill lymphoma cells. It is for people with a type of B-cell non-Hodgkin lymphoma that has come back or not improved after standard treatments.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.